Septin 9 antibody (C-Term)

Catalog No. ABIN390155

The Rabbit Polyclonal anti-Septin 9 antibody has been validated for WB, FACS and IHC (p). It is suitable to detect Septin 9 in samples from Human. There are 2+ publications available.

Quick Overview for Septin 9 antibody (C-Term) (ABIN390155)

Target: Septin 9 (SEPT9)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Septin 9 antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB1931

Product Details anti-Septin 9 Antibody

Binding Specificity: AA 57-85, C-Term

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This SEPT9 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 57-85 amino acids from the C-terminal region of human SEPT9.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000. WB: 1:1000. WB: 1:1000. IHC-P: 1:50~100. IHC-P: 1:50~100. FC: 1:10~50

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.

Expiry Date: 6 months

References for anti-Septin 9 antibody (ABIN390155)

Amir, Golan, Mabjeesh: "Targeted knockdown of SEPT9_v1 inhibits tumor growth and angiogenesis of human prostate cancer cells concomitant with disruption of hypoxia-inducible factor-1 pathway." in: Molecular cancer research : MCR, Vol. 8, Issue 5, pp. 643-52, (2010) (PubMed).

Bennett, Romigh, Eng: "Disruption of transforming growth factor-beta signaling by five frequently methylated genes leads to head and neck squamous cell carcinoma pathogenesis." in: Cancer research, Vol. 69, Issue 24, pp. 9301-5, (2009) (PubMed).

Target Details for Septin 9

Target: Septin 9 (SEPT9)

Alternative Name: SEPT9

Background: The maf oncogene was identified by structural analysis of the AS42 avian transforming retrovirus genome. The Maf family is divided into two subclasses, large Mafs (vMaf, cMaf, MafB and Nrl) and small Mafs (MafF, MafK, and MafG). Both subclasses contain leucinezipper motifs, which allow homodimerization as well as heterodimerization with a variety of other bZip transcription factors. Large Mafs also contain an acidic transactivation domain absent in the small Maf proteins. Although they do not possess inherent transactivation activity, small Maf proteins can act as positive regulators of transcription by targeting transcriptionally active dimerization partners to specific DNA regulatory elements. Conversely, small Mafs can act also as negative regulators of transcription by recruiting transcriptional repressors or by forming homodimers that can replace active dimers. Human MafF was isolated in a yeast one-hybrid system from a human myometrium cDNA library. Human MAFF encodes a 164 amino acids proten. Like other small MAFF proteins, it contains an extended leucine zipper structure and lacks an N-terminal transactivating domain. The three small Maf proteins have been implicated in a number of physiological processes, including development, differentiation, haematopoiesis and stress response. Interestingly, these three proteins regulate the stress response via different mechanisms.

Molecular Weight: 65401

Gene ID: 7975

NCBI Accession: NP_001106963, NP_001106964, NP_001106965, NP_001106966, NP_001106967, NP_001106968, NP_006631

UniProt: Q9UHD8